Evaluation of the Efficacy, Safety and Tolerability of Orally Administered BI 409306, a Novel Phosphodiesterase Type 9 Inhibitor, in Two Randomised Controlled Phase II Studies in Patients With Prodromal and Mild Alzheimer’s Disease
Alzheimer's Research and Therapy - United Kingdom
doi 10.1186/s13195-019-0467-2
Full Text
Open PDFAbstract
Available in full text
Date
February 12, 2019
Authors
Publisher
Springer Science and Business Media LLC